Liquidia Technologies, Inc. Aktie News

Liquidia Corporation ( LQDA ) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 PM EDT Company Participants Roger Jeffs - CEO & Director Rajeev Saggar - Chief Medical Officer Jason Adair - Chief Business Officer Conference Call Participants Richard Channick Rajan Saggar Ricardo Restrepo-Jaramillo Julian Harrison - BTIG, LLC, ...

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results an...

MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast from 2:00 p.m. to 4:30 p.m. Eastern Standard Time.

MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company's executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Boston.

Liquidia Corporation (LQDA) Q2 2025 Earnings Call Transcript

Liquidia stock shot higher Tuesday after its new drug, Yutrepia, widely beat prescription and patient start expectations.

MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on August 12, 2025, to review financial performance a...

Liquidia shipped its first FDA-approved product, Yutrepia for pulmonary hypertension in June entering market worth several billion dollars. Market sentiment remains skeptical, pricing in limited Yutrepia success despite a large addressable market and competitor United Therapeutics' strong sales. Valuation scenarios suggest substantial upside if LQDA captures meaningful market share, but capital...